Abingdon Health  

Sand Hutton
York,  YO41 1LZ

United Kingdom
https://www.abingdonhealth.com
  • Booth: 3838

Our core expertise lies in the development and manufacturing of lateral flow assays and readers. Our manufacturing facilities are ISO13485 and GMP compliant. Using technology taken from our FDA registered and CE marked lateral flow reader, ADxLR5®, we offer customised OEM reader solutions. The reader can be optimised to read multiple lines and labels, and include multiple languages. We also supply Seralite® - FLC in serum and urine, a rapid aid in the diagnosis and monitoring of Multiple Myeloma*, which uses lateral flow and reader technology for the quantitative measurement of kappa and lambda free light chains. The Seralite® Product Range has been extended with the introduction of our Seralite®-FLC ELISA*, providing a higher throughput assay to aid the diagnosis and monitoring of Myeloma. We also supply a nucleic acid lateral flow assay, PCRD. Used as an alternative to using DNA agarose gel electrophoresis PCRD takes 10 minutes to detect successful amplifications. *Not for sale in USA


 Press Releases

  • Abingdon Health announces the appointment of JoyingBio as a distributor of PCRD in China.

    Abingdon Health Ltd is pleased to announce the appointment of JoyingBio (Hangzhou Jiuyang Biotechnology Co., Ltd.) as distributor in China for PCRD nucleic acid lateral flow immunoassays (NALFIA).

    PCRD is a lateral flow immunoassay incorporating antibodies which capture and allow visualisation of double-stranded amplification products containing selected binding partners, FITC (or FAM) and Biotin, as well as DIG and Biotin. This simple method of amplicon detection takes only 10 minutes, and the result is detectable by eye due to an aggregation of carbon particles at the capture lines. PCRD is a rapid, safe and sensitive alternative to ethidium bromide staining of agarose gels.

    JoyingBio specializes in...read more

  • Sebia, the world leader in medical diagnostics by electrophoresis, and Abingdon Health, an in-vitro diagnostic group, today announce that they have entered into a multi-year, exclusive, global distribution agreement. The deal allows Sebia to add Abingdon Health’s Seralite®– FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offering. The financial terms of the agreement have not been disclosed.

    Seralite®– FLC is the most recent generation of rapid, smart and easy-to-operate test for the quantitative measurement of free kappa and free lambda light chains in blood. Serum free light chain (sFLC) testing is prescribed to help detect, diagnose and monitor plasma cell disorders (dyscrasias) such as multiple myeloma, and to monitor the effectiveness of treatments. The test is aimed at clinical laboratories with a small to medium-sized workload for sFLC test requests as well as at clinical laboratories sending requests to referral laboratories, which might result in some countries in delays in receiving patients’ results. It brings superior analytical performance along with cost effectiveness and flexibility.

    To view the full press release please click here.

  • Abingdon Health are pleased to announce the CE marking and FDA registration of their newly available immunoassay reader – ADxLR5® as a Class 1 Medical Device. The ADxLR5® lateral flow device reader has been developed as a next generation technology designed to offer the user the most up to date features required for rapid testing, including a touch screen user interface, barcode sample identification ,stored calibration curve processing and wifi or wired connectivity.

    The launch of the ADxLR5® will support the growth and expansion of the Abingdon Health multiple myeloma assays Seralite®– FLC serum and Seralite®– FLC urine. In addition, the ADxLR5® will be provided as an OEM reader solution for those customers wishing to have a bespoke reader developed alongside the development of lateral flow assays.

    To view the full press release please click here.

    Demonstrations of the reader will take place at our booth (3838) during AACC. Please contact us fo rmore information about the demonstrations. 

  • Abingdon Health announces the registration of its manufacturing facilities as GMP compliant, with the U.S. Food and Drug Administration (FDA), for the design, development and manufacture of lateral flow devices, and device readers for in vitro diagnostic medical use.

    In addition, the Company’s Quality Management System certification encompassing ISO 9001:2008, ISO 13485:2003 and BS EN ISO 13485:2012, has been further extended to cover the design, development and manufacture of lateral flow devices, ELISA kits, reagents and device readers for in vitro diagnostic medical use.

    To read the full press release please click here.


 Products

  • ADxLR5® - Lateral Flow Assay Reader
    Abingdon Health presents our FDA registered and CE marked lateral flow reader, ADxLR5®. The reader incorporates a 10.1 inch touch screen with graphical user interface, icon driven software, USB ports and Ethernet connection. The sample draw with interchangeable and cleanable inserts allows for the reading of a wide range of devices...
           

  • Abingdon Health’s next generation FDA registered and CE marked ADxLR5® Lateral Flow Assay reader incorporates a 10.1 inch touch screen with graphical user interface and icon driven software. The sample draw with interchangeable inserts allows for the reading of a wide range of devices and assays. Connectivity is via 2 USB ports, Ethernet connection or WiFi. The ADxLR5® is the ideal solution for customised lateral flow tests. Our reader can be rapidly adapted for existing assays; alternatively a bespoke reader development can be carried out alongside the development of lateral flow assays. Our assay development team work in conjunction with our reader team to deliver your required lateral flow device specification and a state of the art OEM reader.
     

    To see a demonstration of ADxLR5® at AACC, or for more information, please email info@abingdonhealth.com.

     

  • Seralite –FLC ELISA (Kappa and Lambda Test)
    Abingdon Health presents our new ELISA based κ and λ free light chain (FLC) assays*. Based on the same monoclonal detection Abs utilised in our innovative Seralite®-FLC product, the ELISA format allows laboratories requiring higher sample throughput to measure levels of FLC in the serum of Multiple Myeloma patients. *Not for sale in the USA...
       

  • Abingdon Health is delighted to present our new ELISA based κ and λ free light chains (FLC) assays*. Based on the same monoclonal detection antibodies utilised in our innovative Seralite®- FLC product, the 96 well ELISA format allows laboratories requiring higher throughput of patient samples to accurately measure levels of FLC in the serum of patients with Multiple Myeloma, suspected Myeloma or one of the associated premalignant conditions (MGUS or SMM), whether at diagnosis or in the monitoring of confirmed disease, with the same confidence afforded to them by the Seralite®- FLC assay. This product is the latest addition to Abingdon Health’s portfolio in the field of Haematology Oncology.
    *Not available for sale in the US

    Enquires about Seralite - FLC ELISA (Kappa and Lambda Test) can be directed to info@abingdonhealth.com


 Additional Info

Included in Export Interest Directory?
Yes

 

  •  
    • AACC Annual Scientific Meeting & Clinical Lab Expo Management
    • SPARGO, Inc.
    • Toll Free (800) 564-4220
    • Phone:  (703) 631-6200
    • Fax (703) 563-2691
    • Email:  aaccexhibits@spargoinc.com
  •